Nexien BioPharma Inc (NXEN)

[PBGoodwill]

CRANBURY, N.J. and Mendoza, ARGENTINA, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced additional positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in patients with Pompe disease, an inherited lysosomal storage disorder caused by an enzyme deficiency that leads to accumulation of glycogen (disease substrate) in cells. Patients treated with AT-GAA for up to 18 months showed improvements in six-minute walk test (6MWT) distance and other measures of motor function and muscle strength, stability or increases in forced vital capacity (FVC), and durable reductions in biomarkers of muscle damage and disease substrate. These clinical results are being featured at the 23rd International Annual Congress of the World Muscle Society in an oral platform presentation today, Friday October 5, 2018 at 12:20am ART (11:20am EDT).
The presentation will be given by Professor Benedikt Schoser, senior consultant at the Friedrich-Baur-Institute, Dept. of Neurology at the Ludwig-Maximilians-University of Munich, Germany and Principal Investigator in the ATB200-02 study.

https://www.ptcommunity.com/wire/amicus-therapeutics-announces-positive-18-month-data-pompe-disease-phase-12-study-23rd

https://www.otcmarkets.com/stock/NTVA/news/INTIVA-BioPharma-Retains-Dr-Benedikt-Schoser-as-an-Advisor?id=197903